These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8658641)

  • 41. Alloimmunity and immunosuppression in human graft-versus-host disease.
    Tsoi MS
    Surv Synth Pathol Res; 1984; 3(3):275-80. PubMed ID: 6387855
    [No Abstract]   [Full Text] [Related]  

  • 42. [Synthesis of non-specific immunoglobulins in tolerant animals].
    Sidorov EV; Fontalin LN; Novikova TK; Pevnitskiĭ IA
    Biull Eksp Biol Med; 1977 Feb; 83(2):190-1. PubMed ID: 851617
    [No Abstract]   [Full Text] [Related]  

  • 43. Medawar Prize Lecture: tolerance and graft-vs-host disease: two sides of the same coin.
    Brent L
    Transplant Proc; 1995 Feb; 27(1):12-4. PubMed ID: 7878849
    [No Abstract]   [Full Text] [Related]  

  • 44. Estradiol-induced wasting syndrome in neonatal mice.
    Reilly RW; Thompson JS; Bielski RK; Severson CD
    J Immunol; 1967 Feb; 98(2):321-30. PubMed ID: 6019720
    [No Abstract]   [Full Text] [Related]  

  • 45. Paradigm shift for graft-versus-host disease.
    Ferrara JL
    Bone Marrow Transplant; 1994 Aug; 14(2):183-4. PubMed ID: 7994229
    [No Abstract]   [Full Text] [Related]  

  • 46. Graft-versus-host induced immunosuppression and tissue injury: experimental and theoretical considerations.
    Seemayer TA; Lapp WS
    Surv Synth Pathol Res; 1984; 3(3):254-63. PubMed ID: 6387853
    [No Abstract]   [Full Text] [Related]  

  • 47. Only genuine CD4+CD25+ Tregs may be friends or foes.
    Fietta A; Meloni F
    Blood; 2004 Jun; 103(11):4369-70; author reply 4370-1. PubMed ID: 15155472
    [No Abstract]   [Full Text] [Related]  

  • 48. [Presence of antinuclear serum antibodies in mice thymectomized at birth].
    Brézin C; Cannat A; Sekiguchi M
    Rev Fr Etud Clin Biol; 1965 Oct; 10(8):839-41. PubMed ID: 5852748
    [No Abstract]   [Full Text] [Related]  

  • 49. [The pathogenesis of parabiotic intoxication].
    Shevelev AS; Semenkov VF; Fedosov EA; Mikheeva GD
    Biull Eksp Biol Med; 1969 Jun; 67(6):96-8. PubMed ID: 5399184
    [No Abstract]   [Full Text] [Related]  

  • 50. Parabiotic intoxication in germ-free mice.
    Leonard L; Anderson RE; Ovitz ML
    Nature; 1967 Oct; 216(5112):244-6. PubMed ID: 6057939
    [No Abstract]   [Full Text] [Related]  

  • 51. Neonatal splenectomy: absence of runting in mice.
    Kubai L; Auerbach R
    Nature; 1968 Feb; 217(5127):460. PubMed ID: 5641762
    [No Abstract]   [Full Text] [Related]  

  • 52. The specificity of immunological tolerance.
    Cinader B; St Rose J; Yoshimura M
    Int Arch Allergy Appl Immunol; 1965; 27(6):365-7. PubMed ID: 5834747
    [No Abstract]   [Full Text] [Related]  

  • 53. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Murine models of graft-versus-host disease with features of scleroderma.
    Charley MR; Deng JS
    Immunol Ser; 1989; 46():625-40. PubMed ID: 2488872
    [No Abstract]   [Full Text] [Related]  

  • 55. Induction and analysis of lethal graft-versus-host disease in tolerant mice.
    Végh P; Vizler C; Jánossy T; Savelkoul HF; Nyirati I; Benner R
    Transplant Proc; 1996 Jun; 28(3):1241-3. PubMed ID: 8658641
    [No Abstract]   [Full Text] [Related]  

  • 56. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
    Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.